<DOC>
	<DOCNO>NCT02787863</DOCNO>
	<brief_summary>Goal : examine formation postvaccination immunity evaluate therapeutic effect bacterial vaccine patient inflammation diseases bronchopulmonary system . Objectives study : assessment microbiocenosis mucous membrane upper respiratory tract patient bronchopulmonary pathology use bacterial vaccine . Identification mayor lymphocytes subpopulation , proinflammatory cytokine , inflammatory marker patient dynamic vaccination process . Study profile humoral immune response patient different scheme vaccination . Detection level autoantibody tissue antigens serum vaccinate patient inflammatory disease respiratory tract . Assessment clinic functional status bronchopulmonary system immunized patient . Development methodical recommendation / study guide improvement therapy patient different inflammation disease respiratory tract .</brief_summary>
	<brief_title>Clinical Immunological Efficiency Bacterial Vaccines Adult Patients With Bronchopulmonary Pathology</brief_title>
	<detailed_description>Methods : 1 . IgG-antibodies S.pneumoniae - solid-phase ELISA . 2 . General level IgA , IgM , IgG , IgE serum - radial immunodiffusion . 3 . Phagocytic activity ( granulocyte , monocyte ) , nitroblue tetrazolium test ; activate T-lymphocytes ( CD3+CD69+ ) ; activate B-lymphocytes ( CD3-CD69+ ) ; absolute content leukocytes ; absolute relative content lymphocyte , granulocyte , monocyte , T-lymphocytes ( CD3+ , CD4+ , CD8+ ) , B-lymphocytes ( CD69+ ) ; natural killer ( CD3- , CD16+ , CD56+ ) , activate T-cells ( CD3+ HLA DR ) . 4 . Microbiological examination sputum . 5 . Spirometry . 6 . Determining clinical effectiveness vaccination . - number exacerbation chronic bronchopulmonary pathology year prior vaccination year vaccination ; - number course antibiotic therapy year prior vaccination year immunization ; - number hospitalization acute exacerbation chronic bronchopulmonary disease year prior vaccination year immunization . 7 . Method estimate quality life associate health patient chronic bronchopulmonary pathology . For Arms 1-3 . Screening : collecting complaint , anamnesis , physical examination , X-ray chest , spirometry bronchodilator , ORL examination , ACT-C , ACQ5 , CAT , CCQ-tests , test six-minute walk , clinical analysis blood leukocyte count , allergiamelone ( skin prick test and/or determination specific IgE ) , cytology test nasal secret . Immunological examination ( 1 , 2 , 12 , 60 day ) . CD45 PC7 , CD3 FITC , CD16/32 PE NK , CD4 ECD , CD25 PE , CD19 PE , MHCII ( I-A ) PerCP , TLR2 , TLR4 , TLR7 , TLR3 , TLR9 , IL1B , IL-2 , IL-4 , IL-6 , IL-8 , IL-10 , IFN-gamma , IFN-alpha . ( 1 , 13 , 60 , 180 day ) - IgG IgM level conditional pathogen ELISA method . 1 day - definition respiratory virus PCR oropharynx detachable , microbiological examination sputum/throat crop Evaluation effectiveness investigational drug would base primary secondary performance criterion . To assess primary performance criterion analyze follow indicator : improvement ( recovery ) ; lack effect ; relapse ; impossible estimate . Eradication , presumed eradication , persistence , estimate persistence , recurrence , superinfection , colonization , eradication reinfection , inconclusive result . Continued registration adverse event . For Arms 4-6 . Screening : collecting complaint , anamnesis , physical examination , X-ray chest , clinical analysis blood leukocyte count . ( 1 , 2 , 13 , 60 day ) . CD45 PC7 , CD3 FITC , CD16/32 PE NK , CD4 ECD , CD25 PE , CD19 PE , MHCII ( I-A ) PRRS , TLR2 , TLR4 , TLR7 , TLR3 , TLR9 , IL1B , IL-2 , IL-4 , IL-6 , IL-8 , IL-10 , IFN-gamma , TNF-alpha . ( 1 , 13 , 60 , 180 day ) - IgG IgM level conditional pathogen ELISA method . 1 day - definition respiratory virus PCR oropharynx detachable , microbiological examination sputum/throat crop ; determination S. pneumoniae urine admission . Evaluation effectiveness investigational drug would base primary secondary performance criterion . To assess primary performance criterion analyze follow indicator : improvement ( recovery ) ; lack effect ; relapse ; impossible estimate . Eradication , presumed eradication , persistence , estimate persistence , recurrence , superinfection , colonization , eradication reinfection , inconclusive result . Continued registration adverse event . For Arms 7-9 . Screening : collecting complaint , anamnesis , physical examination , X-ray chest , spirometry bronchodilator , ORL examination , ACT-C , ACQ5 , CAT , CCQ-tests , test six-minute walk , clinical analysis blood leukocyte count , allergiamelone ( skin prick test and/or determination specific IgE ) , cytology test nasal secret . Study content acute phase proteins - C-reactive protein , Alveolitis . Immunological examination ( 1 , 2 , 12 , 60 day ) . CD45 PC7 , CD3 FITC , CD16/32 PE NK , CD4 ECD , CD25 PE , CD19 PE , MHCII ( I-A ) PerCP , TLR2 , TLR4 , TLR7 , TLR3 , TLR9 , IL1B , IL-2 , IL-4 , IL-6 , IL-8 , IL-10 , IFN-gamma , IFN-alpha . ( 1 , 13 , 60 , 180 day ) - IgG IgM level conditional pathogen ELISA method . 1 day - definition respiratory virus PCR oropharynx detachable , microbiological examination sputum/throat crop Evaluation effectiveness investigational drug would base primary secondary performance criterion . To assess primary performance criterion analyze follow indicator : improvement ( recovery ) ; lack effect ; relapse ; impossible estimate . Eradication , presumed eradication , persistence , estimate persistence , recurrence , superinfection , colonization , eradication reinfection , inconclusive result . Continued registration adverse event . Characteristics variable . 1 . The age patient ( year ) : mean ( standard deviation ) [ min ; median ; max ] normally distributed variable ; median [ interquartile lat ] - variable distribution different normal . 2 . Gender : male/female . 3 . Index pack-years . 4 . The severity disease . For COPD : - mild : FEV1≥80 % proper value , index tiffno &lt; 0.7 . - moderate : 50 % ≤FEV1 &lt; 80 % proper value , index tiffno &lt; 0.7 . - severe : 30 % ≤FEV1 &lt; 50 % proper value , index tiffno &lt; 0.7 . - severe : FEV1 &lt; 30 % proper value , index tiffno &lt; 0.7 . For Asthma : - mild intermittent : symptom le 1 time week exacerbation brief , night-time symptom 2 time month FEV1 PSV≥80 % proper value , PSV FEV1 variability &lt; 20 % . - Easy persisting symptom 1 time per week , le 1 time per day ; exacerbation may disturb activity sleep , nocturnal symptom 2 time month FEV1 PSV≥80 % proper value , variability PSV FEV1≤30 % . - Asthma moderate — daily symptom , exacerbation may disturb activity sleep , nocturnal symptom 1 time week , daily dose inhaled β2-agonists short-acting FEV1 PSV 60-80 % proper value , PSV FEV1 variability &gt; 30 % . - Asthma severe daily symptom , frequent exacerbation , frequent nocturnal symptom ASTHMA , limited physical activity , FEV1 PSV≤60 % proper value , PSV FEV1 variability &gt; 30 % . The data source performance spirometry . 5 . Indicators immune status - IgG antibody S. pneumoniae - IgA , g/l [ 0,4-3,5 ] - IgM , g/l [ 0,7-2,8 ] - IgG , g/l [ 8-18 ] - IgE , IU/ml [ &lt; 100 ] - Phagocytic index ( granulocyte ) , % [ 82-90 ] - Phagocytic index ( monocyte ) , % [ 75-85 ] - The participation rate spontaneous NBT-test ( neutrophil ) , % intensity 0.2.e . [ 7-14 ] - The index activity induce NBT-test ( neutrophil ) , % intensity &gt; 0.36.e . [ &gt; 28 ] - The percentage NBT-positive cell spontaneous test , % [ 2-19 ] - Activated T-lymphocytes CD3+CD69+ , % [ 50-69 ] - Activated B-lymphocytes + EKK CD3-CD69+ , % [ 15-34 ] - CEC cond . unit [ 0,055-0,11 ] - White blood cell , 106/l [ 4000-9000 ] - Lymphocytes , 106/l [ 1200-3000 ] - Lymphocytes , % [ 19-37 ] - Granulocyte , 106/l [ 1800-7700 ] - Granulocytes , % [ 40-60 ] - Monocytes , 106/l [ 0-800 ] - Monocytes , % [ 1-6 ] - CD3+ , 106/l [ 800-2200 ] - CD3+ , % [ 55-80 ] - CD3+CD4+ , 106/l [ 600-1600 ] - CD3+CD4+ , % [ 31-49 ] - CD3+CD8+ , 106/l [ 190-650 ] - CD3+CD8+ , % [ 12-30 ] - CD19+ , 106/l [ 100-500 ] - CD19+ , % [ 5-19 ] - CD3-CD16+CD56+ , 106/l [ 150-600 ] - CD3-CD16+CD56+ , % [ 6-20 ] - CD3+CD16+CD56+ , % [ &lt; 10 ] - CD3-HLA DR+ , 106/l [ 60-600 ] - CD3-HLA DR+ , % [ 5-20 ] - CD3+HLA DR+ , % [ &lt; 12 ] - CD45RO . The reference value coefficient sensitization = 0,2 . 6 . Microbiological examination sputum : frequency selection certain microorganism present absolute number case % respective group . 7 . Evaluation early post-vaccination period - The General condition ( satisfactory/unsatisfactory opinion test ) - Local reaction : pain ( n/ % ) , redness ( n/ % , cm ) , consolidation ( n/ % , cm ) - General reaction : - Temperature 37,0-37,5 ( n/ % ) - Temperature 37.6-38,5 ( n/ % ) - A temperature 38.6 &gt; ( n/ % ) - Headache ( n/ % ) - Malaise , fatigue ( n/ % ) - Joint pain ( n/ % ) - Muscle pain ( n/ % ) All adverse event cod use late version international vocabulary standard medical terminology ( MedDRA ) prefer term low level term . 8 . Indices spirometry : - FVC [ ≥80 % proper value ] - FEV1 [ ≥80 % proper value ] - FEV1/FVC index tiffno [ ≥0,7 ] - MMEF25 [ ≥80 % proper value ] - МОС50 [ ≥80 % proper value ] - МОС75 [ ≥80 % proper value ] 9 . Clinical efficacy vaccination : - number acute exacerbation chronic bronchopulmonary pathology year prior vaccination year vaccination - number course antibiotic therapy year prior vaccination year immunization - number hospitalization acute exacerbation chronic bronchopulmonary disease year prior vaccination year immunization . Under chronic bronchopulmonary pathology understand two type disease : COPD bronchial asthma . Under exacerbation chronic bronchopulmonary pathology refers increase symptom dyspnea , cough , sputum , emergence strengthen wheeze whistle chest , feel compression chest , require treatment modification therapy , confirm information initial documentation patient . Under number course antibacterial drug refers number course antibiotic year prior vaccination year vaccination due exacerbation chronic bronchopulmonary disease , also reason associate chronic bronchopulmonary pathology . This information also confirm presence primary record documentation patient . Under hospitalization refers admission subject treatment hospital chronic bronchopulmonary disease , routine emergency indication . Confirmation hospitalization serve medical history disease , entry medical card examinee . In course work gather information hospitalization year year vaccination . 10 . Method estimate quality life associate health For measurement indicator quality life associate health COPD patient prior vaccination year vaccination use sociological research method use SAT test ( COPD Assessment Test ) . The value test 0 10 point indicate significant influence COPD patient 's life , 11 20 point - moderate impact COPD patient 's life , 21 30 point - strong effect COPD patient 's life , result 31 point COPD exert extremely strong influence life patient . Assessment quality life patient bronchial asthma carry dynamic use questionnaire ACQ-5 ( Asthma Control Questionnaire ) . Total score ACQ-5 calculate arithmetic mean 5 response : &lt; 0,5-0,75 - good control asthma , 0,75-1,5 - partial control asthma , &gt; 1.5 uncontrolled asthma . PRIMARY SOURCE VERIFICATION ACT Protasov Andrey Dmitrievich , M.D. , assistant professor Department General Clinical Microbiology , Immunology Allergology State-Funded Educational Institution Higher Professional Education `` Samara State Medical University '' ( SFEI HPE `` SSMU '' ) , applicant seek Doctor Medical Sciences degree base thesis entitle `` Systemic approach vaccine prophylaxis vaccine therapy pneumococcal infection patient chronic bronchopulmonary pathology '' ( 14.03.09 - `` clinical immunology allergology '' ; 14.01.25 - `` pulmonology '' ) . Thesis advisory panel include : Chairman panel : professor Department Intermediate Level Therapy , Doctor Medical Sciences , professor V.V . Simerzin ; Members panel : - Head Department Family Medicine Advanced Training Institute , Doctor Medical Sciences , associate professor V.I . Kupaev ; - Associate professor Department Propedeutic Therapy A.V . Germanov , M.D . ; - Professor Department General Clinical Pathology , anatomical pathology pathological physiology , Doctor Medical Sciences , professor M.I . Panina , Reviewed follow dissertation material : 1 . Extracts medical history ( outpatient card ) - 219 . 2 . Data patient clinical examination ( protocols patient question examination , clinical diagnosis , questionnaire result ) . 3 . Data patient laboratory investigation , spirometry result , sputum culture ( copy ) . 4 . Signed patient 's informed consent form authorize health care intervention . 5 . Copies research paper - 37 . 6 . Materials statistical analysis study result electronic form . The author carry pilot , prospective , non-randomized , one-center , non-placebo-controlled study enrol total 219 patient chronic bronchopulmonary pathology follow 4 year . The study conduct specialist consult diagnostic clinical center State-Funded Educational Institution Higher Professional Education `` Samara State Medical University '' Ministry Healthcare Russia collaboration Federal State-Funded Research Institute `` Moscow Scientific Research Institute Vaccines Sera name I.I . Mechnikov '' . The investigation commonly use clinical trial include physical examination , laboratory , immunological microbiological investigation , assessment functional test health-related quality life parameter dynamic include short-term ( one-year ) long-term ( four-year ) follow-up adult patient chronic bronchopulmonary pathology ( e.g. , chronic obstructive pulmonary disease , bronchial asthma ) backdrop use different pneumococcal vaccination regimen . Statistical analysis carry use StatPlus 2009 Professional 5.8.4 apply software package appropriate statistical method . Study result present dissertation fully match data primary medical record comply international system unit ( SI ) . The correctness parameter confirm correspond entry primary document . The author personally involved step study analysis result . The statistical significance authenticity primary source material raise doubt . The result statistical analysis fully agree data present table illustrate dissertation . All result present dissertation abstract publish scientific paper meet abstract . The author personally involved study clinical , microbiological immunological effect vaccination pneumococcal infection patient chronic bronchopulmonary pathology effect different vaccination regimen dynamic functional test parameter short- long-term quality life outcome . He also develop scientifically sound regimen use pneumococcal vaccine patient chronic bronchopulmonary pathology . The presence complete set primary document sufficient statistical analysis study result allow u conclude data obtain correct conclusion recommendation justify . No violation requirement Higher Attestation Commission ( HAC ) Ministry Education Science Russia applicable primary document find . The thesis advisory panel come conclusion completeness quality submit material conformance topic content dissertation A.D. Protasov `` Systemic approach vaccine prophylaxis vaccine therapy pneumococcal infection patient chronic bronchopulmonary pathology '' ( 14.03.09 - `` clinical immunology allergology '' ; 14.01.25 - `` pulmonology '' ) . The panel chairman : Professor Department Intermediate Level Therapy `` SFEI HPE `` SSMU '' , Doctor Medical Sciences , professor V.V . Simerzin The panel member : Head Department Family Medicine Advanced Training Institute `` SFEI HPE `` SSMU '' , Doctor Medical Sciences , associate professor V.I . Kupaev Professor Department General Clinical Pathology , anatomical pathology pathological physiology `` SFEI HPE `` SSMU '' , Doctor Medical Sciences , professor M.I . Panina Associate professor Department Propedeutic Therapy `` SFEI HPE `` SSMU '' A.V . Germanov , M.D .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Individuals sex 18 year diagnosis communityacquired pneumonia , COPD Bronchial Asthma ; The presence sign date informed consent participate clinical study ; The ability perform requirement Protocol ; For woman childbearing age negative result pregnancy test vaccination . Diagnostic criterion : communityacquired pneumonia : presence radiologically confirm infiltration lung tissue ; presence least two follow clinical sign : acute fever early disease ( temperature &gt; 38.0°C ) , cough sputum , physical sign pneumonia ( focus crepitate and/or fine bubble rale , bronchial breathe hard , shorten percussion sound ) , leukocytosis &gt; 10*10 9 /l and/or stab shift &gt; 10 % ; occurrence disease outside hospital organize group ( nurse home , sanatorium , etc. ) . COPD : dyspnea : progressive ( worsens time ) , increase exertion , persistent ; chronic cough ( may appear sporadically may unproductive ) ; chronic expectoration ; impact risk factor medical history ( Smoking , occupational dust pollutant chemical ) ; widespread wheeze auscultation chest and/or distant wheezing chest ; family history COPD ; spirometric data confirm presence fix bronchial obstruction . Vaccination pneumococcal infection anamnesis ; Application preparation immune globulin blood transfusion within last three month prior clinical study ; Prolonged use ( 14 day ) immunosuppressant immunosuppressive drug within 6 month prior start study ; Any confirm suspected immunosuppressive immunodeficient condition , include HIV infection ; A history currently hematologic cancer ; A positive reaction HIV infection , viral hepatitis B hepatitis C ; The presence respiratory , cardiovascular insufficiency , impair liver kidney function , establish physical examination visit number 1 ; Pronounced congenital defect serious chronic disease acute stage , include clinically important exacerbation chronic disease liver , kidney , cardiovascular , nervous system , mental disease metabolic disorder , confirm history objective examination ( pulmonary : cystic fibrosis , lung abscess , empyema , active tuberculosis ; extrapulmonary : congestive heart failure , malabsorption , chronic renal hepatic failure , cirrhosis , malignancy , immunodeficiency , cirrhosis liver ) ; Severe allergic reaction anamnesis autoimmune disease ; The presence acute infectious and/or communicable illness within 1 month prior study ; History chronic alcohol abuse and/or drug use ; Exacerbation chronic disease ; Breastfeeding ; Pregnancy ; Participation clinical study within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Polioxidonium</keyword>
</DOC>